AVDL Share Price Performance
US$21.35
11.41 (114.79%)
33.4% overvalued intrinsic discount
US$16.00
Fair Value
Price US$21.35
AnalystLowTarget US$16.00
AnalystConsensusTarget US$21.06
AnalystHighTarget US$31.47
Fair ValueUS$16.00
Share Pricen/a
Avadel Pharmaceuticals plc Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 20 Fair Values set on narratives written by author
AVDL Community Narratives
AN
Fair Value US$16 33.4% overvalued intrinsic discount
Reliance On Single Therapy Will Trigger Competition Yet Secure Recovery
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$21.06 1.4% overvalued intrinsic discount
Analysts Adjust Avadel Pharmaceuticals Price Target Amid Acquisition and Ongoing Market Developments
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
Fair Value US$31.47 32.2% undervalued intrinsic discount
LUMRYZ Launch Will Fuel Long-Term Orphan Drug Market Growth
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Analysts Adjust Avadel Pharmaceuticals Price Target Amid Acquisition and Ongoing Market Developments
Key Takeaways LUMRYZ's adoption and differentiated dosing profile are fueling strong growth and establishing a sustainable competitive edge amid rising sleep disorder awareness and demand for innovation. Expansion into new indications and strengthened intellectual property position enhance long-term revenue potential, diversification, and protection against competitive threats.Read more
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
US$21.06
1.4% overvalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
24.09% p.a.
Profit Margin
35.91%
Future PE
15.27x
Price in 2028
US$25.84
LUMRYZ Launch Will Fuel Long-Term Orphan Drug Market Growth
Key Takeaways Rapid LUMRYZ adoption and superior patient retention could significantly outpace consensus growth expectations, expanding both market share and overall category size. Legal wins, favorable market trends, and operational strength position Avadel for accelerated growth, greater pricing power, and strategic expansion opportunities.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$31.47
32.2% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue
41.99% p.a.
Profit Margin
29.2%
Future PE
20.75x
Price in 2028
US$38.59
Reliance On Single Therapy Will Trigger Competition Yet Secure Recovery
Key Takeaways Dependence on a single product and lack of pipeline diversity make future growth vulnerable to competition, regulatory setbacks, and market changes. Rising drug pricing pressures and high operational costs threaten long-term profitability despite strong revenue growth and favorable market trends.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$16
33.4% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue
23.42% p.a.
Profit Margin
20.33%
Future PE
23.07x
Price in 2028
US$19.62
Trending Discussion
Recently Updated Narratives
AN
AVDL: Competing Acquisition Proposals Will Shape Outcomes Amid Industry Uncertainty
Fair Value: US$21.06 1.4% overvalued intrinsic discount
11 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Reliance On Single Therapy Will Trigger Competition Yet Secure Recovery
Fair Value: US$16 33.4% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
LUMRYZ Launch Will Fuel Long-Term Orphan Drug Market Growth
Fair Value: US$31.47 32.2% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Avadel Pharmaceuticals plc Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.0028
- 94.91%
- -0.11%
- 35.5%
About AVDL
- Founded
- 2015
- Employees
- 188
- CEO
- WebsiteView website
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
